Blog
RSS FeedPosted by Michael Wonder on 04 Nov 2021
NICE recommends Namuscla for NHS to treat genetic disorder
4 November 2021 - NICE has published draft guidance which recommends a rebranded form of the drug mexiletine (Namuscla), for ...
Posted by Michael Wonder on 03 Nov 2021
NICE releases guidance on medicine for patients with thyroid cancer
3 November 2021 - Selpercatinib is used to treat patients with advanced RET fusion positive thyroid cancer. ...
Posted by Michael Wonder on 02 Nov 2021
Pricing vaccines and drugs in Europe: worth differentiating?
1 November 2021 - The COVID-19 pandemic has recently brought to the forefront the vital importance of vaccines, of which Europe ...
Posted by Michael Wonder on 28 Oct 2021
NICE publishes final guidance for Janssen's apalutamide
28 October 2021 - Final guidance for two indications. ...
Posted by Michael Wonder on 26 Oct 2021
NICE draft guidance does not recommend tucatinib for advanced breast cancer
26 October 2021 - NICE has today published draft guidance for public consultation which does not recommend tucatinib (Tukysa; Seagen), in ...
Posted by Michael Wonder on 18 Oct 2021
NICE approves Ofev for PF-ILD
18 October 2021 - NICE has recommended Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of adult patients with chronic fibrosing ...
Posted by Michael Wonder on 18 Oct 2021
New asthma drug approved on NHS branded a ‘wonder drug’
18 October 2021 - NICE has issued a Final Appraisal Determination recommending dupilumab as an add-on maintenance treatment for severe ...
Posted by Michael Wonder on 15 Oct 2021
NICE clears Opdivo for resected oesophageal or gastro-oesophageal junction cancer
15 October 2021 - The UK NICE has recommended BMS' Opdivo (nivolumab) as a treatment option for certain resected oesophageal ...
Posted by Michael Wonder on 11 Oct 2021
Consternation as NICE rejects Janssen MS drug Ponvory
8 October 2021 - NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, ...
Posted by Michael Wonder on 11 Oct 2021
NICE backs Rinvoq for moderate active RA
11 October 2021 - AbbVie has announced that its oral therapy Rinvoq (upadacitinib) has received a positive recommendation from NICE ...
Posted by Michael Wonder on 06 Oct 2021
NICE terminates another appraisal for a Roche medicine
6 October 2021 - The sixth termination of the appraisal of a Roche medicine. ...
Posted by Michael Wonder on 05 Oct 2021
Venetoclax comes close to gaining support from NICE
4 October 2021 - A proposal from AbbVie for a Cancer Drugs Fund listing may get it over the line. ...
Posted by Michael Wonder on 05 Oct 2021
NICE recommends first treatment in two decades for sickle cell disease
5 October 2021 - Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance ...
Posted by Michael Wonder on 30 Sep 2021
NICE terminates another two appraisals
29 September 2021 - Four terminations for the month. ...
Posted by Michael Wonder on 30 Sep 2021
People with advanced or metastatic urothelial cancer to get life-extending treatment
30 September 2021 - Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for ...